相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。PharmVar GeneFocus: CYP3A5
Cristina Rodriguez-Antona et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2022)
Functional Characterization of 40 CYP3A4 Variants by Assessing Midazolam 1′-Hydroxylation and Testosterone 6β-Hydroxylation
Masaki Kumondai et al.
DRUG METABOLISM AND DISPOSITION (2021)
Toward predicting CYP2D6-mediated variable drug response from CYP2D6 gene sequencing data
Maaike van der Lee et al.
SCIENCE TRANSLATIONAL MEDICINE (2021)
CYP3A4*22 Genotyping in Clinical Practice: Ready for Implementation?
Tessa A. M. Mulder et al.
FRONTIERS IN GENETICS (2021)
Variability of voriconazole concentrations in patients with hematopoietic stem cell transplantation and hematological malignancies: influence of loading dose, procalcitonin, and pregnane X receptor polymorphisms
Guangting Zeng et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2020)
Transcriptional regulation of CYP3A4 by nuclear receptors in human hepatocytes under hypoxia
Xuechun Yuan et al.
DRUG METABOLISM REVIEWS (2020)
Influence of POR*28 Polymorphisms on CYP3A5*3-Associated Variations in Tacrolimus Blood Levels at an Early Stage after Liver Transplantation
Takahiro Nakamura et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Variant discovery using next-generation sequencing and its future role in pharmacogenetics
Laura E. Russell et al.
PHARMACOGENOMICS (2020)
Inherited and Acquired Determinants of Hepatic CYP3A Activity in Humans
Johannes Matthaei et al.
FRONTIERS IN GENETICS (2020)
Technologies for Pharmacogenomics: A Review
Maaike van der Lee et al.
GENES (2020)
Transfer learning enables prediction of CYP2D6 haplotype function
Gregory McInnes et al.
PLOS COMPUTATIONAL BIOLOGY (2020)
Functional characterization of 21 CYP3A4 variants on amiodarone metabolism in vitro
Cheng-Cheng Yang et al.
XENOBIOTICA (2019)
Functional characterization of 27 CYP3A4 protein variants to metabolize regorafenib in vitro
Ying-Hui Li et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2019)
Single-Molecule Sequencing: Towards Clinical Applications
Adam Ameur et al.
TRENDS IN BIOTECHNOLOGY (2019)
Impact of CYP3A5, POR, and CYP2C19 Polymorphisms on Trough Concentration to Dose Ratio of Tacrolimus in Allogeneic Hematopoietic Stem Cell Transplantation
Kimitaka Suetsugu et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Targeted next generation sequencing as a tool for precision medicine
Markus Gulilat et al.
BMC MEDICAL GENOMICS (2019)
Characterization of Genetic Variation in CYP3A4 on the Metabolism of Cabozantinib in Vitro
Qian-meng Lin et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2019)
A primer on deep learning in genomics
James Zou et al.
NATURE GENETICS (2019)
Genome-wide association study identifies the common variants in CYP3A4 and CYP3A5 responsible for variation in tacrolimus trough concentration in Caucasian kidney transplant recipients
W. S. Oetting et al.
PHARMACOGENOMICS JOURNAL (2018)
Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers
Carmen Belmonte et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2018)
Relevance of CYP3A4*20, UGT1A1*37 and UGT1A1*28 variants in irinotecan-induced severe toxicity
Pau Riera et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Mathematical Models in the Description of Pregnane X Receptor (PXR)-Regulated Cytochrome P450 Enzyme Induction
Jurjen Duintjer Tebbens et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Tacrolimus Population Pharmacokinetics and Multiple CYP3A5 Genotypes in Black and White Renal Transplant Recipients
Olivia Campagne et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Increase in tacrolimus exposure after steroid tapering is influenced by CYP3A5 and pregnane X receptor genetic polymorphisms in renal transplant recipients
Frank Stifft et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2018)
Genetic variations of the xenoreceptors NR1I2 and NR1I3 and their effect on drug disposition and response variability
Litaty Cephanoee Mbatchi et al.
PHARMACOGENOMICS (2018)
Detection of a rare CYP3A4 variant in a transplant patient characterized by a tacrolimus poor metabolizer phenotype
Nuria Lloberas et al.
PHARMACOGENOMICS (2018)
Functional Characterization of 22 CYP3A4 Protein Variants to Metabolize Ibrutinib In Vitro
Ren-ai Xu et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2018)
TSPYL Family Regulates CYP17A1 and CYP3A4 Expression: Potential Mechanism Contributing to Abiraterone Response in Metastatic Castration-Resistant Prostate Cancer
Sisi Qin et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
Targeted Next-Generation Sequencing for Comprehensive Genetic Profiling of Pharmacogenes
S. M. Han et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC)
Kelly E. Caudle et al.
GENETICS IN MEDICINE (2017)
Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response
Mikael Kozyra et al.
GENETICS IN MEDICINE (2017)
Long-Term Influence of CYP3A5, CYP3A4, ABCB1, and NR1I2 Polymorphisms on Tacrolimus Concentration in Chinese Renal Transplant Recipients
Fei Liu et al.
GENETIC TESTING AND MOLECULAR BIOMARKERS (2017)
Analysis of common polymorphisms within NR1I2 and NR1I3 genes and tacrolimus dose-adjusted concentration in stable kidney transplant recipients
Mateusz Kurzawski et al.
PHARMACOGENETICS AND GENOMICS (2017)
Pharmacogentics-based personalized therapy: Levels of evidence and recommendations from French Network of Pharmacogenetics (RNPGx)
Nicolas Picard et al.
THERAPIE (2017)
Differential Regulation of CYP3A4 and CYP3A5 and its Implication in Drug Discovery
Ogheneochukome Lolodi et al.
CURRENT DRUG METABOLISM (2017)
Influence of a critical single nucleotide polymorphism on nuclear receptor PXR-promoter function
Manjul Rana et al.
CELL BIOLOGY INTERNATIONAL (2017)
Genomewide Association Study of Tacrolimus Concentrations in African American Kidney Transplant Recipients Identifies Multiple CYP3A5 Alleles
W. S. Oetting et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2016)
Inflammation and Organ Failure Severely Affect Midazolam Clearance in Critically Ill Children
Nienke J. Vet et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2016)
CYP3A activity: towards dose adaptation to the individual
Nicolas Hohmann et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2016)
Effect of pregnane X receptor polymorphisms on tacrolimus blood concentrations and the resulting adverse reactions in kidney transplantation recipients
Z. P. Wang et al.
GENETICS AND MOLECULAR RESEARCH (2016)
Expression of CYP3A4 and CYP3A7 in Human Foetal Tissues and its Correlation with Nuclear Receptors
Stina Betts et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2015)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing
K. A. Birdwell et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2015)
Epigenetic Regulation of Cytochrome P450 Enzymes and Clinical Implication
Xiaojing Tang et al.
CURRENT DRUG METABOLISM (2015)
The CYP3A4*22 C>T single nucleotide polymorphism is associated with reduced midazolam and tacrolimus clearance in stable renal allograft recipients
H. de Jonge et al.
PHARMACOGENOMICS JOURNAL (2015)
High frequency and founder effect of the CYP3A4*20 loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzyme
M. Apellaniz-Ruiz et al.
PHARMACOGENOMICS JOURNAL (2015)
miRNA-27b levels are associated with CYP3A activity in vitro and in vivo
Lena Ekstrom et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2015)
Plasma Levels of 25-Hydroxyvitamin D3 and In Vivo Markers of Cytochrome P450 3A Activity in Swedes and Koreans: Effects of a Genetic Polymorphism and Oral Contraceptives
Hanna Nylen et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2014)
Identification and Characterization of a Defective CYP3A4 Genotype in a Kidney Transplant Patient With Severely Diminished Tacrolimus Clearance
A. N. Werk et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Association of Hemoglobin Levels, CYP3A5, and NR1I3 Gene Polymorphisms with Tacrolimus Pharmacokinetics in Liver Transplant Patients
Dawei Chen et al.
DRUG METABOLISM AND PHARMACOKINETICS (2014)
Association of CYP3A4*18B and CYP3A5*3 polymorphism with cyclosporine-related liver injury in Chinese renal transplant recipients
Hua-wen Xin et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2014)
The Effect of CYP3A4*IG Allele on the Pharmacokinetics of Atorvastatin in Chinese Han Patients With Coronary Heart Disease
Bao-xia He et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Pregnane X receptor and hepatocyte nuclear factor 4α polymorphisms are cooperatively associated with carbamazepine autoinduction
Junji Saruwatari et al.
PHARMACOGENETICS AND GENOMICS (2014)
The Effect of microRNAs in the Regulation of Human CYP3A4: a Systematic Study using a Mathematical Model
Zhiyun Wei et al.
SCIENTIFIC REPORTS (2014)
Differential regulation of CYP3A4 promoter activity by a new class of natural product derivatives binding to pregnane X receptor
Monimoy Banerjee et al.
BIOCHEMICAL PHARMACOLOGY (2013)
PXR polymorphisms and their impact on pharmacokinetics/pharmacodynamics of repaglinide in healthy Chinese volunteers
Qing-qing Du et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Genome-wide association study reveals a complex genetic architecture underpinning-induced CYP3A4 enzyme activity
Nilufer Rahmioglu et al.
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS (2013)
Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis
Xiao-cong Zuo et al.
PHARMACOGENETICS AND GENOMICS (2013)
CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy
Laure Elens et al.
PHARMACOGENOMICS (2013)
Genetic variation in the PPARA gene is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study
Catherine E. de Keyser et al.
PHARMACOGENOMICS (2013)
CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin
Laure Elens et al.
PHARMACOGENOMICS (2013)
Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
Ulrich M. Zanger et al.
PHARMACOLOGY & THERAPEUTICS (2013)
Pharmacogenomics of Cytochrome P450 3A4: Recent Progress Toward the “Missing Heritability” Problem
Kathrin Klein et al.
Frontiers in Genetics (2013)
Intestinal CYP3A4 and midazolam disposition in vivo associate with VDR polymorphisms and show seasonal variation
Ranjit K. Thirumaran et al.
BIOCHEMICAL PHARMACOLOGY (2012)
Nuclear receptors in the multidrug resistance through the regulation of drug-metabolizing enzymes and drug transporters
Yakun Chen et al.
BIOCHEMICAL PHARMACOLOGY (2012)
Population Pharmacokinetics and Pharmacogenetics of Everolimus in Renal Transplant Patients
Dirk Jan A.R. Moes et al.
CLINICAL PHARMACOKINETICS (2012)
PPARA: A Novel Genetic Determinant of CYP3A4 In Vitro and In Vivo
Kathrin Klein et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Effect of CYP3A4*1G on the fentanyl consumption for intravenous patient-controlled analgesia after total abdominal hysterectomy in Chinese Han population
Z-L Dong et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2012)
The new CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patients
Laure Elens et al.
PHARMACOGENETICS AND GENOMICS (2012)
Impact of CYP3A4*1G polymorphism on metabolism of fentanyl in Chinese patients undergoing lower abdominal surgery
Ruimei Yuan et al.
CLINICA CHIMICA ACTA (2011)
Pharmacogenetics: From Bench to Byte-An Update of Guidelines
J. J. Swen et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Genetic epidemiology of induced CYP3A4 activity
Nilufer Rahmioglu et al.
PHARMACOGENETICS AND GENOMICS (2011)
Impact of the CYP3A4*1G polymorphism and its combination with CYP3A5 genotypes on tacrolimus pharmacokinetics in renal transplant patients
Masatomo Miura et al.
PHARMACOGENOMICS (2011)
Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients
Laure Elens et al.
PHARMACOGENOMICS (2011)
The P450 oxidoreductase*28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients
Hylke de Jonge et al.
PHARMACOGENOMICS (2011)
Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs
D. Wang et al.
PHARMACOGENOMICS JOURNAL (2011)
The missing linkage: what pharmacogenetic associations are left to find in CYP3A?
Minoli Perera
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2010)
Using SIFT and PolyPhen to Predict Loss-of-Function and Gain-of-Function Mutations
Sarah E. Flanagan et al.
GENETIC TESTING AND MOLECULAR BIOMARKERS (2010)
MicroRNAs Regulate Human Hepatocyte Nuclear Factor 4α, Modulating the Expression of Metabolic Enzymes and Cell Cycle
Shingo Takagi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Genetic Predictors of Interindividual Variability in Hepatic CYP3A4 Expression
Vishal Lamba et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2010)
Genetic Polymorphisms and Individualized Tacrolimus Dosing
M. A. Lopez-Montenegro Soria et al.
TRANSPLANTATION PROCEEDINGS (2010)
Identification of polymorphisms in the 3′-untranslated region of the human pregnane X receptor (PXR) gene associated with variability in cytochrome P450 3A (CYP3A) metabolism
L. Oleson et al.
XENOBIOTICA (2010)
Tacrolimus Population Pharmacokinetic-Pharmacogenetic Analysis and Bayesian Estimation in Renal Transplant Recipients
Khaled Benkali et al.
CLINICAL PHARMACOKINETICS (2009)
The CYP3A4*18 Genotype in the Cytochrome P450 3A4 Gene, a Rapid Metabolizer of Sex Steroids, Is Associated With Low Bone Mineral Density
Y. S. Kang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
MicroRNAs Regulate CYP3A4 Expression via Direct and Indirect Targeting
Yu-Zhuo Pan et al.
DRUG METABOLISM AND DISPOSITION (2009)
Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation
Ulrich M. Zanger et al.
ANALYTICAL AND BIOANALYTICAL CHEMISTRY (2008)
Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C→T) with reduced concentrations of unboosted atazanavir
Marco Siccardi et al.
CLINICAL INFECTIOUS DISEASES (2008)
Novel single nucleotide polymorphisms in the promoter and intron 1 of human pregnane X receptor/NR1l2 and their association with CYP3A4 expression
Jatinder Lamba et al.
DRUG METABOLISM AND DISPOSITION (2008)
Identification of NR1I2 genetic variation using resequencing
Cristi R. King et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Molecular mechanism of basal CYP3A4 regulation by hepatocyte nuclear factor 4α :: Evidence for direct regulation in the intestine
Heike Tegude et al.
DRUG METABOLISM AND DISPOSITION (2007)
CAR and PXR: The xenobiotic-sensing receptors
Yoav E. Timsit et al.
STEROIDS (2007)
The human cytochrome P450 sub-family: Transcriptional regulation, inter-individual variation and interaction networks
Nick Plant
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2007)
Nuclear receptor expression in fetal and pediatric liver: Correlation with CYP3A expression
CA Vyhlidal et al.
DRUG METABOLISM AND DISPOSITION (2006)
The journey from NADPH-cytochrome P450 oxidoreductase to nitric oxide synthases
BSS Masters
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
Functional analysis of four naturally occurring variants of human constitutive androstane receptor
S Ikeda et al.
MOLECULAR GENETICS AND METABOLISM (2005)
Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism
HX Zheng et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA
I Koch et al.
DRUG METABOLISM AND DISPOSITION (2002)
Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7
JA Williams et al.
DRUG METABOLISM AND DISPOSITION (2002)
Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism
YS Lin et al.
MOLECULAR PHARMACOLOGY (2002)
In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration
YS Lin et al.
PHARMACOGENETICS (2001)
The genetic determinants of the CYP3A5 polymorphism
E Hustert et al.
PHARMACOGENETICS (2001)
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression
P Kuehl et al.
NATURE GENETICS (2001)
Cytochrome P450 regulation by hepatocyte nuclear factor 4 in human hepatocytes:: A study using adenovirus-mediated antisense targeting
R Jover et al.
HEPATOLOGY (2001)
Genomic organization of the human CYP3A locus:: identification of a new, inducible CYP3A gene
K Gellner et al.
PHARMACOGENETICS (2001)
Evaluation of the genetic component of variability in CYP3A4 activity:: a repeated drug administration method
V Özdemir et al.
PHARMACOGENETICS (2000)
分享论文
